Leerink Partnrs Analysts Cut Earnings Estimates for Insulet

Insulet Co. (NASDAQ:PODD) – Analysts at Leerink Partnrs cut their Q1 2025 EPS estimates for Insulet in a note issued to investors on Thursday, February 20th. Leerink Partnrs analyst M. Kratky now anticipates that the medical instruments supplier will post earnings per share of $0.65 for the quarter, down from their previous forecast of $0.69. The consensus estimate for Insulet’s current full-year earnings is $3.92 per share. Leerink Partnrs also issued estimates for Insulet’s FY2027 earnings at $6.89 EPS, FY2028 earnings at $8.41 EPS and FY2029 earnings at $9.87 EPS.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. The business had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%.

A number of other research firms have also recently issued reports on PODD. Barclays lifted their target price on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Piper Sandler lifted their price target on shares of Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a research report on Friday. TD Cowen lifted their price target on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Sanford C. Bernstein began coverage on shares of Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target on the stock. Finally, Morgan Stanley lifted their price target on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $289.06.

Insulet Stock Performance

PODD stock opened at $282.80 on Monday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock has a market cap of $19.84 billion, a P/E ratio of 48.84, a P/E/G ratio of 3.62 and a beta of 1.23. The firm has a 50 day simple moving average of $272.98 and a 200 day simple moving average of $247.87. Insulet has a 52 week low of $160.19 and a 52 week high of $289.46.

Institutional Investors Weigh In On Insulet

Several institutional investors and hedge funds have recently made changes to their positions in the company. Integrated Wealth Concepts LLC boosted its stake in shares of Insulet by 1.7% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock valued at $596,000 after purchasing an additional 42 shares in the last quarter. Horizon Investments LLC boosted its stake in shares of Insulet by 3.1% in the 4th quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier’s stock valued at $362,000 after purchasing an additional 42 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Insulet by 1.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock valued at $1,146,000 after purchasing an additional 43 shares in the last quarter. Glenmede Trust Co. NA boosted its stake in shares of Insulet by 2.3% in the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock valued at $484,000 after purchasing an additional 47 shares in the last quarter. Finally, Graypoint LLC boosted its stake in shares of Insulet by 5.3% in the 4th quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock valued at $243,000 after purchasing an additional 47 shares in the last quarter.

Insider Buying and Selling at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This trade represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.